HALOZYME THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-02-18
- HALOZYME THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $2.58M.
- HALOZYME THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was -$175.00K.
- HALOZYME THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- HALOZYME THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
- HALOZYME THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$2.49M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $0.00 10-K · filed 2025-02-18 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $2.40M derived: sum of 2 quarters · filed 2025-02-18 | $0.00 derived: sum of 3 quarters · filed 2025-02-18 | $0.00 10-K · filed 2025-02-18 |
| 2023-09-30 | -$175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$2.58M derived: sum of 2 quarters · filed 2024-10-31 | -$2.58M 10-Q · filed 2024-10-31 | -$3.50M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.40M 10-Q · filed 2024-08-06 | -$3.33M derived: sum of 3 quarters · filed 2025-02-18 | -$3.78M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | -$921.00K derived: sum of 2 quarters · filed 2025-02-18 | -$1.37M derived: sum of 3 quarters · filed 2025-02-18 | -$2.00M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | -$921.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$1.37M derived: sum of 2 quarters · filed 2025-02-18 | -$2.00M derived: sum of 3 quarters · filed 2025-02-18 | -$2.49M 10-K · filed 2025-02-18 |
| 2022-09-30 | -$451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.07M derived: sum of 2 quarters · filed 2023-11-06 | -$1.57M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | -$623.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.12M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$499.00K 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | -$498.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$997.00K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$499.00K 10-Q · filed 2022-08-09 |